A test that analyzes free-floating DNA in the blood may be able to detect early-stage lung cancer, a preliminary report from the ongoing Circulating Cell-Free Genome Atlas (CCGA) study suggests. Lead study author Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute: “There is an unmet need globally for early-detection tests for lung cancer that can be easily implemented by health-care…
With the help of a new radioactive tracer, doctors can predict with more than 80 percent accuracy how well a widely-used lung cancer drug will combat tumors, according to researchers at Stanford. The researchers developed a PET scan-compatible imaging agent engineered to seek out a specific mutation found in nonsmall cell lung cancer (which accounts for about 80 percent of lung cancers), bind to…
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer. The test, called CancerSEEK, is a unique noninvasive, multianalyte test that simultaneously evaluates levels of eight cancer proteins and the presence of cancer gene mutations from circulating DNA in the blood. The test is aimed at…
Although targeted therapies have produced dramatic advances in our ability to control some types of advanced lung cancer, growth of the disease in the brain remains a major problem. Radiation is often used to treat deposits in the brain, but the best technique to deliver radiation can be controversial. Whole-brain radiation therapy, as its name suggest, treats the entire brain but can be…
Patients with unresectable, or inoperable, lung cancer are often given a dismal prognosis, with low rates of survival beyond a few years. Researchers exploring combination therapies have recently discovered improved survival rates by up to one year when patients treated with a newly formulated chemotherapy regimen are also given radiation therapy.
Lung cancer is the cancer that causes the highest mortality worldwide, claiming an estimated 1.7 million patients annually, with 270,000 of those deaths in Europe.
Billy Boyle, Founder and CEO of Owlstone Medical, a diagnostics company developing a breathalyzer for disease, is to be awarded the Royal Academy of Engineering’s prestigious Silver Medal. The award recognizes engineer Billy’s work in spearheading the development of the company’s Breath Biopsy platform and driving a vision to save 100,000 lives and $1.5 billion in healthcare costs.
Menarini-Silicon Biosystems announced the company’s DEPArray single-cell isolation technology played a key role in a study conducted by researchers from The University of Manchester to develop a model for predicting whether small-cell lung cancer patients will be sensitive or resistant to initial chemotherapy treatment.
Since lung diseases tend to be complex, imaging is a crucial diagnostic tool. While computed tomography has become the standard modality, which is frequently used outside hospital settings, specialised MRI diagnostics remains the preserve of large university medical centres.
The University of Montreal Hospital Research Centre (CRCHUM) is launching a major international clinical trial to test a minimally invasive and safer surgical approach for patients with lung cancer: video-assisted thoracoscopic (VATS) lobectomy with ultrasonic pulmonary artery sealing.
Researchers at Massachusetts Institute of Technology research center in Singapore have developed a new microfluidic device that tests the effects of electric fields on cancer cells. They observed that a range of low-intensity, middle-frequency electric fields effectively stopped breast and lung cancer cells from growing and spreading, while having no adverse effect on neighboring healthy cells.
A simple blood test can rapidly and accurately detect mutations in two key genes in non-small cell lung tumors, researchers at Dana-Farber Cancer Institute and other institutions report in a new study – demonstrating the test’s potential as a clinical tool for identifying patients who can benefit from drugs targeting those mutations.
Small cell lung cancer is not usually detected until it is at an advanced stage, when metastases have already formed. Chemotherapy is very effective initially but, within a year, cancer recurs and this time does not respond to a course of chemotherapy. The research group headed by Gerhard Hamilton, University Department of Surgery at MedUni Vienna, has now managed to identify the reason for this…
Johns Hopkins scientists report they have developed an antibody against a specific cellular gateway that suppresses lung tumor cell growth and breast cancer metastasis in transplanted tumor experiments in mice, according to a new study published in the February issue of Nature Communications.
Interstitial lung diseases (ILD) are rare – yet they are far more difficult to diagnose and highly variable. Professor Julien Dinkel, consultant at the Institute of Clinical Radiology, Ludwig Maximilian University Hospital in Munich, deals with these rarities.
Randox Laboratories and Biosystems International have announced the beginning of clinical validation of a lung cancer early detection test.
One goal of immunotherapy is to rally a patient’s often over-burdened immune cells to effectively attack a tumor. Among foot soldiers on the immune front line is a subpopulation of white blood cells called “patrolling monocytes,” whose job is to cruise the bloodstream, cart off cellular debris, and block invasion of a less benign population of inflammatory cells.
Researchers compared an immunotherapy and a chemotherapy drug in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease continued to progress after first-line chemotherapy. They found that nivolumab improved overall survival and was generally well tolerated. The results are significant because options for patients whose lung cancer progresses after initial treatment are…
With more than 50,000 newly diagnosed cases each year, lung cancer is one of the most common types of cancer in Germany. As yet, however, very few statistics are available on the care situation of lung cancer sufferers and the associated costs. Scientists at the Helmholtz Zentrum München have now analyzed comprehensive health insurance data in order to discover the cost of the disease and which…
Lung cancer is the leading cause of cancer death worldwide, responsible for some 1.59 million deaths a year. That figure is due, in part, to the fact that the cancer often returns after what, at first, seems to be successful treatment. And the recurring cancer is often resistant to the chemotherapy and other drugs that originally drove it into remission. According to new research by the Weizmann…
Researchers at the San Diego Supercomputer Center (SDSC) and the Moores Cancer Center at the University of California, San Diego, have described for the first time the molecular mechanism of cancer development caused by well-known "resistance" mutations in the gene called epidermal growth factor receptor (EGFR).
Nanoparticles are extremely small particles that can be modified for a variety of uses in the medical field. For example, nanoparticles can be engineered to be able to transport medicines specifically to the disease site while not interfering with healthy body parts.
Screening for lung cancer saves lives. This fact has been documented by outcomes of the U.S. National Lung Screening Trial (NLST) which showed a 20% reduction in lung cancer-specific deaths in patients who had a chest CT screening. What is controversial is how to establish the radiology resources needed to perform exams for all the people who need it and then how to pay for the exams.
To avoid any misunderstanding, ten years from today CT and MRI will still be the pillars of lung imaging. However, Hans-Ulrich Kauczor, Professor of Radiology and Medical Director of the radiology clinic at Heidelberg University Hospital, is convinced the emphasis will have changed.
Cancer specialists everywhere increasingly face new findings from molecular biology. Genetic profiling of tumours opens up entirely new perspectives on the disease. How to cope with and integrate new insights into cancer diagnosis and treatment was among key issues discussed at the 2nd European Forum on Oncology, held in Berlin this May